Clinical Research
5 articles on Clinical Research, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1 Weight Loss: Why Consistency Matters for Ozempic & Wegovy
Recent preclinical research suggests that inconsistent use of GLP-1 medications like Ozempic and Wegovy may diminish their effectiveness over time. Discover the science behind adherence and how to optimize your therapy.
9 min read
Semaglutide NAION Risk: New Study Findings for Weight Loss Patients
A recent analysis published in JAMA Ophthalmology reveals a significant increase in NAION risk associated with semaglutide compared to SGLT2 inhibitors, though absolute risk remains low.
8 min read
Duodenal Resurfacing May Prevent Weight Regain After Stopping Ozempic
New research presented at Digestive Disease Week 2026 suggests a minimally invasive 'gut reset' procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Ozempic and Wegovy. The findings address a major challenge in obesity treatment: weight regain after stopping therapy.
7 min read
GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Allodynia
Emerging reports suggest GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) may trigger unusual sensory side effects, including painful skin sensitivity known as dysesthesia and allodynia. A new case series provides critical insights for patients and clinicians.
7 min read
Real-World Data Highlights Heart Benefits of Diabetes Drugs Semaglutide and Tirzepatide
New research indicates that semaglutide and tirzepatide, drugs used for managing type 2 diabetes, exhibit heart-protective effects in real-world settings, mirroring findings from clinical trials. The study highlights the cardiovascular benefits these medications offer to patients in everyday clinical practice.
4 min read